PH12022553314A1 - Anti-egfr antibody drug conjugates - Google Patents

Anti-egfr antibody drug conjugates

Info

Publication number
PH12022553314A1
PH12022553314A1 PH1/2022/553314A PH12022553314A PH12022553314A1 PH 12022553314 A1 PH12022553314 A1 PH 12022553314A1 PH 12022553314 A PH12022553314 A PH 12022553314A PH 12022553314 A1 PH12022553314 A1 PH 12022553314A1
Authority
PH
Philippines
Prior art keywords
drug conjugates
antibody drug
egfr antibody
adcs
egfr
Prior art date
Application number
PH1/2022/553314A
Inventor
Erwin R Boghaert
Milan Bruncko
Andrew S Judd
Andrew C Phillips
Andrew J Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PH12022553314A1 publication Critical patent/PH12022553314A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
PH1/2022/553314A 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates PH12022553314A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347416P 2016-06-08 2016-06-08
PCT/US2017/036368 WO2017214282A1 (en) 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates

Publications (1)

Publication Number Publication Date
PH12022553314A1 true PH12022553314A1 (en) 2024-05-27

Family

ID=59078219

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2018/502602A PH12018502602B1 (en) 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates
PH1/2022/553314A PH12022553314A1 (en) 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PH1/2018/502602A PH12018502602B1 (en) 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates

Country Status (21)

Country Link
US (3) US20190343961A1 (en)
EP (2) EP4104865A1 (en)
JP (4) JP2019521106A (en)
KR (2) KR20230035690A (en)
CN (4) CN116059394A (en)
AU (2) AU2017277517A1 (en)
BR (1) BR112018075636A2 (en)
CA (1) CA3027178A1 (en)
CL (2) CL2018003527A1 (en)
CO (1) CO2018013497A2 (en)
CR (1) CR20180614A (en)
DO (2) DOP2018000272A (en)
EC (1) ECSP19000157A (en)
IL (3) IL308054A (en)
MX (2) MX2018015286A (en)
PE (1) PE20190512A1 (en)
PH (2) PH12018502602B1 (en)
RU (1) RU2018147224A (en)
SG (2) SG11201810970WA (en)
TW (3) TW202423486A (en)
WO (1) WO2017214282A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468615A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
EP4364754A3 (en) 2016-06-08 2025-02-12 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468616A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
WO2018218004A1 (en) * 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
CN119613486A (en) * 2019-05-20 2025-03-14 诺华股份有限公司 Antibody drug conjugates with linkers comprising hydrophilic groups
AU2020279230A1 (en) 2019-05-20 2021-12-02 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020233174A1 (en) 2019-05-20 2020-11-26 烟台迈百瑞国际生物医药有限公司 One-pot preparation process for antibody drug conjugate intermediate
KR102787433B1 (en) 2020-01-30 2025-03-27 성균관대학교산학협력단 Antibody-drug conjugate comprising immune checkpoint inhibitor and exosome secretion inhibitor and Pharmaceutical composition comprising the same
RS65811B1 (en) * 2020-05-19 2024-08-30 Servier Lab Para-amino-benzyl linkers, process for their preparation and their use in conjugates
US20240269304A1 (en) 2020-11-24 2024-08-15 Novartis Ag Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
UY39610A (en) 2021-01-20 2022-08-31 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
EP4329819A4 (en) * 2021-04-26 2025-09-24 Univ California COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
MX2023014683A (en) * 2021-06-22 2024-01-12 Regeneron Pharma Anti-egfrviii antibody drug conjugates and uses thereof.
CN117580846A (en) * 2022-04-29 2024-02-20 石药集团中奇制药技术（石家庄）有限公司 Compounds with liver-targeted delivery effects and oligonucleotide conjugates thereof
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates
AR129380A1 (en) 2022-05-20 2024-08-21 Novartis Ag ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USING THE SAME
CN118873678A (en) 2023-01-18 2024-11-01 泰励生物科技（上海）有限公司 Antibody-drug conjugates and their uses
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
US12178876B2 (en) 2023-04-18 2024-12-31 Astrazeneca, Ab Conjugates comprising cleavable linkers
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1726514A (en) 1926-11-01 1929-08-27 Firm Ferd Liebschner & Sohn Picker for looms
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE68921982T4 (en) 1988-06-14 1996-04-25 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
FI903489A7 (en) 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
NZ523476A (en) 2000-06-28 2004-04-30 Glycofi Inc Methods for humanizing glycosylation of recombinant glycoproteins expressed in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli Anti-a-beta antibodies
PL213948B1 (en) 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
ES2347959T3 (en) 2003-02-20 2010-11-26 Seattle Genetics, Inc. ANTI-CD70-FARMACO ANTIBODIES CONJUGATES AND THEIR USE FOR CANCER TREATMENT.
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
DK1912671T3 (en) 2005-07-18 2017-11-27 Seattle Genetics Inc BETA-glucuronide-LINKER-drug conjugates
KR20080114709A (en) 2006-02-02 2008-12-31 신타가 비.브이. Water Soluble CC-1065 Analogues and Their Conjugates
WO2009073445A2 (en) 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
KR20120057588A (en) 2009-05-28 2012-06-05 메르사나 테라퓨틱스, 인코포레이티드 Polyal drug conjugates comprising variable rate-releasing linkers
JP2013528665A (en) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド Modified polymers for delivery of polynucleotides, methods for their production, and methods of their use
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (en) * 2011-10-14 2017-02-21 艾伯維有限公司 Apoptosis-inducing agent for treating cancer and immune and autoimmune diseases
CN104244718A (en) 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 Antibody-drug conjugates and related compounds, compositions, and methods
CN104024236A (en) 2011-12-23 2014-09-03 摩萨那医疗公司 Pharmaceutical formulations for fumagillin derivative-phf conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
ES2983109T3 (en) 2012-05-15 2024-10-21 Seagen Inc Self-stabilizing linker conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
SG11201607746QA (en) * 2014-03-21 2016-10-28 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
US20160339117A1 (en) 2014-12-09 2016-11-24 Abbvie Inc. BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
BR112017012342A2 (en) * 2014-12-09 2018-02-27 Abbvie Inc bcl-x1 inhibitory compounds and antibody-drug conjugates including the same
EP3229844B1 (en) * 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors

Also Published As

Publication number Publication date
CO2018013497A2 (en) 2019-02-08
DOP2018000272A (en) 2019-01-31
TW202423486A (en) 2024-06-16
AU2017277517A1 (en) 2019-01-03
US20190343961A1 (en) 2019-11-14
PH12018502602A1 (en) 2019-09-30
US20230077680A1 (en) 2023-03-16
RU2018147224A3 (en) 2020-10-14
CL2018003527A1 (en) 2019-03-15
KR20190015526A (en) 2019-02-13
SG10201914060WA (en) 2020-03-30
IL308054A (en) 2023-12-01
JP2025032192A (en) 2025-03-11
SG11201810970WA (en) 2019-01-30
CN116059202A (en) 2023-05-05
IL263571A (en) 2019-01-31
PH12018502602B1 (en) 2023-08-16
MX2018015286A (en) 2019-08-12
TW202320860A (en) 2023-06-01
EP3468996B1 (en) 2022-05-04
ECSP19000157A (en) 2019-01-31
JP2022058351A (en) 2022-04-12
EP3468996A1 (en) 2019-04-17
CN109563168A (en) 2019-04-02
US20250213685A1 (en) 2025-07-03
CR20180614A (en) 2019-07-29
MX2022007807A (en) 2022-07-19
AU2024205004A1 (en) 2024-08-08
WO2017214282A1 (en) 2017-12-14
RU2018147224A (en) 2020-07-14
BR112018075636A2 (en) 2019-04-09
CN116059201A (en) 2023-05-05
CA3027178A1 (en) 2017-12-14
KR20230035690A (en) 2023-03-14
CL2019002270A1 (en) 2019-11-15
PE20190512A1 (en) 2019-04-10
CN116059394A (en) 2023-05-05
JP2019521106A (en) 2019-07-25
JP2023166395A (en) 2023-11-21
DOP2022000182A (en) 2022-09-30
TW201806626A (en) 2018-03-01
IL291073A (en) 2022-05-01
EP4104865A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
PH12018502602B1 (en) Anti-egfr antibody drug conjugates
MX2018015284A (en) Anti-egfr antibody drug conjugates.
MX2018015280A (en) ANTIBODY CONJUGATES AND ANTI-EGFR DRUG.
MX2021010471A (en) Anti-egfr antibodies and antibody drug conjugates.
MX2018015272A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2018015268A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2018015274A (en) Anti-cd98 antibodies and antibody drug conjugates.
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2017016169A (en) Anti-her2 antibodies and methods of use.
MX2017011344A (en) Engineered site-specific antibodies and methods of use.
HK1233205A1 (en) Anti-egfr antibodies and antibody drug conjugates